Market Overview
The Global Respiratory Care Devices Market is projected to reach USD 27.8 billion in 2025 and is further expected to expand significantly, attaining a value of USD 60.5 billion by 2034, growing at a compound annual growth rate (CAGR) of 9.0%.
This growth is driven by the rising prevalence of chronic respiratory diseases, increasing demand for home healthcare solutions, technological advancements in diagnostic and therapeutic respiratory devices, and greater adoption of portable and non-invasive systems across hospitals, clinics, and homecare settings.
The global respiratory care devices industry is advancing rapidly, driven by the increasing prevalence of chronic respiratory illnesses such as asthma, chronic obstructive pulmonary disease (COPD), and sleep apnea. Technological innovation is at the forefront, with portable oxygen concentrators, smart inhalers, non-invasive ventilators, and connected monitoring systems transforming how patients receive and manage care. The expansion of
telehealth and remote respiratory monitoring has accelerated, particularly in the aftermath of global health emergencies, as healthcare providers aim to reduce hospital dependency and improve at-home treatment capabilities.
Opportunities are emerging in developing regions where urbanization, industrialization, and aging populations are contributing to higher respiratory disease incidence. The demand for compact, energy-efficient devices suited for resource-limited settings is opening pathways for manufacturers to introduce affordable, adaptable solutions. Increased integration of artificial intelligence and sensor-based technologies is enabling predictive maintenance of devices and personalized treatment adjustments, improving patient adherence and therapy effectiveness.
Despite the strong momentum, the industry faces barriers such as a shortage of trained respiratory therapists, low treatment adherence rates, and regulatory complexities across different regions. In some countries, inconsistent reimbursement structures limit patient access to advanced equipment. Device manufacturers must also navigate the challenge of designing products that meet stringent safety standards while remaining cost-effective.
Overall, growth prospects are underpinned by rising health awareness, supportive government health programs, environmental health concerns, and the steady shift toward preventive and home-based respiratory care. As healthcare systems worldwide focus on reducing hospital congestion and managing long-term conditions more efficiently, the adoption of respiratory care devices is expected to broaden significantly across both developed and emerging markets.
The US Respiratory Care Devices Market
The US Respiratory Care Devices Market is projected to reach USD 8.0 billion in 2025 at a compound annual growth rate of 8.5% over its forecast period.
In the United States, respiratory care devices are a critical component of managing a broad spectrum of lung-related conditions, including COPD, asthma, interstitial lung diseases, and sleep-disordered breathing. According to national health surveillance data, COPD remains a leading cause of morbidity, with higher prevalence among older adults and women. Asthma continues to affect millions of Americans, resulting in substantial emergency care visits and hospitalizations each year. Chronic lower respiratory diseases are consistently ranked among the top causes of death, underscoring the need for accessible and effective care solutions.
Demographic patterns reveal that aging populations, individuals with a history of smoking, and communities exposed to poor air quality are at higher risk for respiratory complications. Certain ethnic and socioeconomic groups also experience disproportionate burdens, highlighting the importance of targeted interventions. Public health initiatives focusing on early diagnosis, smoking cessation, and air pollution reduction are aligned with the increasing adoption of advanced respiratory devices.
The U.S. benefits from a well-developed healthcare infrastructure, specialized respiratory care training programs, and strong regulatory oversight, which supports the introduction of safe, high-performance devices. Federal agencies actively promote innovation through research funding and safety standards, fostering the development of patient-centered technologies such as wearable oxygen systems, portable ventilators, and intelligent monitoring tools. These demographic and policy advantages position the U.S. market for sustained adoption of next-generation respiratory care devices across hospitals, clinics, and home-care environments.
The Europe Respiratory Care Devices Market
The Europe Respiratory Care Devices Market is estimated to be valued at USD 4.1 billion in 2025 and is further anticipated to reach USD 8.3 billion by 2034 at a CAGR of 8.0%.
Across Europe, chronic respiratory diseases present a significant public health challenge, particularly COPD, asthma, and pneumonia. Health statistics show that the prevalence of chronic lower respiratory conditions is generally higher among older adults and women, with certain Eastern and Southern European countries reporting above-average incidence rates. Pneumonia continues to cause hundreds of thousands of deaths annually, especially in elderly populations, making early intervention a priority.
Europe’s demographic profile is marked by an aging population, urbanization, and persistent exposure to environmental pollutants, all of which elevate respiratory health risks. This trend increases demand for medical technologies that can facilitate long-term disease management outside hospital settings. Portable oxygen concentrators, home-use non-invasive ventilators, and advanced nebulizer systems are becoming increasingly important in meeting the needs of patients who require continuous or periodic respiratory support.
The European healthcare system is well-positioned to adopt these solutions due to its emphasis on universal access, preventive care, and coordinated treatment pathways. Regulatory standards, such as CE certification requirements for medical devices, ensure that respiratory care products meet stringent safety and performance criteria before reaching the market. Air quality regulations, anti-smoking policies, and vaccination programs further reinforce a prevention-focused approach.
By combining a strong public health infrastructure with policy-driven disease prevention and management strategies, Europe offers an environment conducive to expanding the use of innovative respiratory care technologies, especially in home-care and community-based healthcare models.
The Japan Respiratory Care Devices Market
The Japan Respiratory Care Devices Market is projected to be valued at USD 1.6 billion in 2025. It is further expected to witness subsequent growth in the upcoming period, holding USD 3.3 billion in 2034 at a CAGR of 8.1%.
Japan’s respiratory care devices market is shaped by both demographic realities and distinctive disease patterns. The country has one of the world’s most rapidly aging populations, with a large proportion of citizens over 65, many of whom are at increased risk of respiratory illness due to age-related decline in lung function. Pneumonia remains a leading cause of death among older adults, and seasonal surges in influenza and other respiratory infections add to the healthcare burden.
Japan also faces unique respiratory health concerns, such as diffuse panbronchiolitis, a chronic lung condition seen more frequently in East Asian populations. Historical industrial pollution events, such as Yokkaichi asthma, have heightened public awareness of air quality’s impact on lung health. These experiences contribute to strong public demand for respiratory monitoring and preventive care.
The healthcare system’s emphasis on early detection and continuous management supports the widespread use of advanced respiratory devices, from high-precision ventilators in hospitals to compact home oxygen systems for long-term therapy. Technological sophistication, combined with strong regulatory oversight, ensures that devices entering the market meet exacting safety and efficacy standards.
Government health agencies encourage the adoption of innovative treatments, including newer vaccines and AI-enabled diagnostic tools, to reduce the incidence and severity of respiratory illnesses. These policies, alongside a well-developed healthcare delivery network, provide a fertile environment for both domestic and international manufacturers to expand their respiratory device offerings in Japan, particularly in preventive care and home-based treatment solutions.
Global Respiratory Care Devices Market: Key Takeaways
- Global Market Size Insights: The Global Respiratory Care Devices Market size is estimated to have a value of USD 27.8 billion in 2025 and is expected to reach USD 60.5 billion by the end of 2034.
- North America Market Size Insights: North America has the largest market share for the Global Respiratory Care Devices Market, with a share of about 35.1% in 2025.
- The US Market Size Insights: The US Respiratory Care Devices Market is projected to be valued at USD 8.0 billion in 2025. It is expected to witness subsequent growth in the upcoming period as it holds USD 16.5 billion in 2034 at a CAGR of 8.5%.
- Regional Insights: Some of the major key players in the Global Respiratory Care Devices Market are Massimo Corporation, Teleflex Incorporated, ResMed Inc. and many others.
- The Global Market Growth Rate: The market is growing at a CAGR of 9.0 percent over the forecasted period.
Global Respiratory Care Devices Market: Use Cases
- Portable Oxygen Therapy for COPD: Patients with chronic obstructive pulmonary disease use portable oxygen concentrators with real-time flow adjustment sensors, ensuring continuous therapy during daily activities and travel, while reducing reliance on hospital visits.
- Smart CPAP for Sleep Apnea: Individuals with sleep apnea use intelligent CPAP machines that monitor breathing patterns, send adherence data to healthcare providers, and automatically adjust air pressure to optimize comfort and therapeutic outcomes.
- Community Lung Function Screening: Rural health programs utilize handheld spirometers to screen populations for early signs of obstructive lung disease, enabling timely treatment and reducing disease progression in underserved areas.
- Compact Ventilators for Emergency Response: Mobile healthcare units and field hospitals deploy multi-function ventilators that combine oxygen delivery, suction, and patient monitoring in one portable system for rapid emergency care.
- Wearable Oxygen Monitoring in Elderly Care: Seniors in assisted living facilities wear continuous pulse oximetry devices with wireless alert systems, allowing caregivers to quickly respond to drops in oxygen saturation and prevent severe respiratory complications.
Global Respiratory Care Devices Market: Stats & Facts
World Health Organization (WHO)
- COPD deaths: COPD caused about 3.23 million deaths worldwide in 2019.
- Rank of COPD: COPD was the 3rd leading cause of death globally in 2019.
- Asthma prevalence: ~262 million people were living with asthma globally in 2019.
- Ambient air pollution: Fine-particle air pollution was associated with ~4.2 million deaths in 2019 worldwide.
- Household air pollution: Exposure to household air pollution contributed to ~3.2 million deaths in 2019.
- Child pneumonia: Pneumonia killed ~740,000 children under 5 in 2019.
- COPD geography: >90% of COPD deaths occur in low- and middle-income countries.
- Tuberculosis: TB caused ~1.3 million deaths in 2022, remaining a major infectious cause of respiratory mortality.
U.S. Centers for Disease Control and Prevention (CDC)
- Asthma (all ages): ~25 million people in the U.S. have asthma (roughly 1 in 13).
- Asthma in children: ~5 million U.S. children currently have asthma.
- Adult asthma prevalence: Around 8% of U.S. adults currently have asthma.
- COPD diagnosed: >16 million U.S. adults have been diagnosed with COPD (many more undiagnosed).
- CLRD mortality: Chronic lower respiratory diseases remain among the leading causes of death in the U.S., with ~140–150 thousand deaths annually in recent years.
- Asthma ED visits: Asthma accounts for ~1.6 million emergency department visits in the U.S. each year.
- Smoking (risk factor): Cigarette smoking among U.S. adults has fallen to ~11–12% in recent years, yet remains a major COPD/asthma risk driver.
National Institutes of Health (NIH) / National Heart, Lung, and Blood Institute (NHLBI)
- Asthma costs: Asthma has been estimated to cost the U.S. ~USD 80+ billion annually in medical expenses, missed work/school, and deaths (official NIH estimate).
- Idiopathic Pulmonary Fibrosis: Approximately 100,000 people in the U.S. are affected by IPF, a progressive interstitial lung disease.
- Sleep apnea burden: NIH cites tens of millions of U.S. adults with obstructive sleep apnea, a key driver of demand for diagnostic and PAP/CPAP therapy devices.
Eurostat (European Union)
- Share of deaths: Diseases of the respiratory system accounted for ~7–8% of all deaths in the EU (pre-pandemic baseline, 2019).
- Age gradient: EU data show markedly higher respiratory mortality rates in older age groups, reflecting device demand for long-term oxygen therapy and ventilation support.
- Gender pattern: Prevalence of chronic lower respiratory diseases (excluding asthma) in Europe shows slightly higher rates among women than men in survey data.
European Respiratory Society (ERS) – European Lung White Book/Reports
- Asthma in Europe: ~30 million people in Europe are estimated to have asthma.
- COPD prevalence: Population-based studies across Europe commonly report COPD prevalence in adults of ~4–10%, varying by country and methodology.
- Healthcare burden: Respiratory diseases account for a substantial share of hospital admissions and healthcare costs across EU health systems, reflecting sustained device utilization.
Australian Institute of Health and Welfare (AIHW)
- Asthma prevalence: ~2.7 million Australians (about 1 in 9–10) were living with asthma in recent reporting years.
- COPD hospital impact: COPD is a leading cause of potentially preventable hospitalizations among older Australians, underscoring demand for home oxygen and ventilation aids.
Statistics Canada / Government of Canada
- Asthma prevalence: ~3.8 million Canadians (roughly 1 in 10) report a diagnosis of asthma.
- COPD prevalence: ~2 million Canadians are living with COPD, with prevalence rising sharply after age 65.
Japan – Ministry of Health, Labour and Welfare (MHLW) / Statistics Bureau of Japan
- Population aging: ~29% of Japan’s population is 65+, creating one of the world’s highest demographic risk profiles for respiratory morbidity and device demand.
- Pneumonia mortality: Pneumonia remains a top cause of death in Japan among older adults, accounting for a significant share of elderly mortality in official vital statistics.
Global Initiative for Asthma (GINA) – International Clinical Body
- Global asthma impact: GINA notes hundreds of millions affected by asthma, with major gaps in control and adherence, sustaining long-term need for inhalers, spacers, and peak-flow monitoring.
- Severe asthma: 5–10% of asthma patients have severe disease, yet they account for disproportionate healthcare use, driving specialized device and biologic therapy integration.
- Exacerbations: Poor asthma control leads to millions of exacerbations annually worldwide, many requiring nebulization and oxygen therapy in acute settings.
Global Initiative for Chronic Obstructive Lung Disease (GOLD) – International Clinical Body
- Underdiagnosis: GOLD highlights substantial underdiagnosis of COPD, with millions undetected globally—supporting broader spirometry deployment and earlier device-supported care.
- Risk factors: Tobacco smoke, biomass fuel exposure, and ambient pollution remain the dominant COPD risk factors, aligning device demand with prevention and long-term oxygen therapy strategies.
- Exacerbation burden: Frequent COPD exacerbations are linked to higher hospitalization risk and mortality, increasing utilization of nebulizers, oxygen systems, and non-invasive ventilation.
Global Respiratory Care Devices Market: Market Dynamics
Driving Factors in the Global Respiratory Care Devices Market
Rising Prevalence of Chronic Respiratory Diseases
The growing global burden of chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and sleep apnea is a primary driver for respiratory care devices. According to the World Health Organization, COPD is currently the third leading cause of death worldwide, causing over 3 million deaths annually.
Lifestyle factors such as smoking, occupational exposure to dust and chemicals, and environmental pollution are significantly increasing the incidence of these conditions. With aging populations more susceptible to respiratory complications, demand for oxygen therapy equipment, inhalers, nebulizers, and non-invasive ventilation devices is escalating. Healthcare systems are prioritizing early diagnosis and treatment, leading to higher adoption of portable respiratory care solutions for home healthcare settings.
Increasing Adoption of Home Healthcare and Telemonitoring
A significant growth driver is the increasing shift towards home-based respiratory care, supported by advancements in telemedicine and remote monitoring technologies. Portable oxygen concentrators, CPAP/BiPAP machines, and smart inhalers allow patients to manage conditions without frequent hospital visits, reducing healthcare costs and improving convenience. Aging populations, coupled with rising hospital bed shortages, have accelerated the adoption of at-home respiratory therapy solutions.
Additionally, government reimbursement policies and insurance coverage for home respiratory care in developed countries further fuel this trend. The COVID-19 pandemic has reinforced the importance of remote patient monitoring, prompting medical device companies to integrate wireless connectivity and data tracking features into respiratory devices, creating a connected ecosystem for continuous patient care.
Restraints in the Global Respiratory Care Devices Market
High Cost of Advanced Respiratory Care Devices and Limited Reimbursement
The high cost of technologically advanced respiratory care devices, such as ventilators, high-flow oxygen therapy systems, and portable concentrators, remains a significant barrier to adoption, especially in low- and middle-income countries. Although these devices offer superior patient outcomes, their affordability is limited in regions with poor healthcare funding or limited reimbursement policies.
Even in developed economies, insurance coverage often does not fully cover the expense of home-based respiratory devices, placing a financial burden on patients. Hospitals and clinics in resource-constrained areas may opt for refurbished or basic models, limiting access to the latest technology.
Regulatory Hurdles and Product Approval Delays
The respiratory care devices industry faces strict regulatory requirements across different countries, which can slow down product approvals and market entry. Authorities such as the U.S. FDA, European Medicines Agency (EMA), and other national health bodies require extensive clinical validation to ensure device safety and efficacy. While these regulations are essential for patient protection, the lengthy approval timelines can delay the introduction of innovative products, reducing the ability of manufacturers to respond quickly to market needs.
Compliance with multiple country-specific standards adds complexity and increases R&D costs. Smaller manufacturers may struggle to meet these regulatory demands, limiting innovation diversity. Furthermore, frequent updates in guidelines, particularly during health crises like COVID-19, create additional uncertainty for product developers.
Opportunities in the Global Respiratory Care Devices Market
Technological Advancements in Portable and Home-Based Respiratory Devices
The growing shift towards home healthcare creates a major opportunity for manufacturers to develop advanced, lightweight, and portable respiratory care devices. Patients with chronic respiratory diseases, such as COPD and asthma, increasingly prefer home-based solutions that allow greater mobility, independence, and comfort while reducing hospital visits.
The integration of telemonitoring, AI-enabled respiratory analytics, and Bluetooth connectivity in portable oxygen concentrators, CPAP/BiPAP machines, and nebulizers enables continuous tracking of lung function and therapy adherence. This also allows physicians to adjust treatment remotely, improving disease management. The rising geriatric population, who are more vulnerable to respiratory ailments, will further fuel demand for home-based respiratory devices.
Expansion in Emerging Markets with Increasing Healthcare Investments
Emerging economies in Asia-Pacific, Latin America, and the Middle East are rapidly increasing investments in healthcare infrastructure and medical device accessibility. Many of these countries have high levels of air pollution, rising smoking prevalence, and growing rates of respiratory illnesses, creating a strong need for respiratory care solutions. Urbanization, coupled with industrialization, has worsened air quality in cities, leading to an increase in asthma and COPD cases.
Governments are improving public healthcare spending, introducing reimbursement policies for respiratory devices, and partnering with global manufacturers to improve device availability. Moreover, public awareness campaigns by organizations like WHO and national health bodies are driving early diagnosis and treatment adoption. Manufacturers expanding into these regions can leverage localized manufacturing, cost-effective product designs, and training programs for healthcare providers.
Trends in the Global Respiratory Care Devices Market
Integration of Smart and AI-Enabled Respiratory Devices
The respiratory care devices market is undergoing a transformation driven by the integration of AI, IoT, and cloud-based monitoring systems. Smart ventilators, oxygen concentrators, and CPAP/BiPAP machines now offer continuous remote monitoring, real-time performance analytics, and predictive maintenance capabilities. These features improve patient adherence, optimize therapy, and reduce healthcare provider workload.
AI algorithms are being used to predict respiratory deterioration in patients with COPD, asthma, or sleep apnea, enabling timely interventions and reducing hospital admissions. Moreover, integration with telehealth platforms facilitates virtual respiratory therapy sessions and remote adjustments to device settings, especially critical for patients in rural or underserved areas.
Shift Towards Home-Based and Portable Respiratory Solutions
A significant trend reshaping the market is the strong demand for compact, lightweight, and battery-efficient respiratory devices designed for home use and travel. The COVID-19 pandemic accelerated the preference for decentralized respiratory care, and patients with chronic respiratory diseases now prefer solutions that support independent living. Portable oxygen concentrators, wearable nebulizers, and travel-friendly non-invasive ventilation systems are gaining traction.
The portability factor allows patients to maintain mobility and quality of life while ensuring consistent therapy adherence. Home-based solutions reduce hospitalization costs, minimize exposure to infectious environments, and help healthcare systems manage capacity during peak demand periods. The integration of portability with connectivity features ensures patients remain under physician supervision even outside traditional healthcare facilities.
Research Scope and Analysis
By Product Analysis
The therapeutic devices segment is projected to lead the global respiratory care devices market with the largest revenue share of 36.0% in 2025. This segment comprises ventilators, nebulizers, oxygen delivery devices, humidifiers, positive airway pressure (PAP) systems, capnographs, and other advanced respiratory equipment. The demand is driven by the segment’s ability to treat respiratory conditions by assisting or enhancing breathing efficiency, whether in acute or chronic settings.
Ventilators remain indispensable for critically ill patients unable to breathe independently, particularly those with acute respiratory distress syndrome (ARDS), severe pneumonia, or post-surgical complications. They are typically available in two main categories adult ventilators and infant ventilators catering to varying clinical needs. Nebulizers play a crucial role in delivering aerosolized medication directly to the lungs, providing fast relief for asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.
Oxygen concentrators and humidifiers also contribute significantly to managing hypoxemia and maintaining airway moisture. The monitoring devices segment including pulse oximeters, spirometers, and capnography systems is expected to witness robust growth. Pulse oximeters, in particular, have become essential for continuous oxygen saturation monitoring, both in clinical and home environments.
Consumables and accessories, such as masks, tubing, filters, and humidification chambers, ensure optimal device performance and patient comfort, creating a steady recurring revenue stream. Growing awareness, technological innovation, and the increasing prevalence of respiratory disorders continue to bolster the therapeutic devices segment’s market leadership.
By Application Analysis
The hospital segment is anticipated to dominate the respiratory care devices market with the largest revenue share of 31.5% in 2025. This dominance is attributed to the frequent hospitalization of elderly patients and individuals with acute or chronic respiratory conditions requiring advanced monitoring and intensive care. Hospitals serve as primary centers for emergency interventions, ventilator support, and complex pulmonary procedures. The availability of specialized pulmonary units, skilled respiratory therapists, and integrated diagnostic facilities ensures comprehensive treatment, further driving adoption.
Additionally, the segment benefits from public-private healthcare partnerships, rapid improvements in hospital infrastructure, and greater access to advanced respiratory technologies in both urban and semi-urban areas. Hospitals also play a vital role in post-operative respiratory support and the management of patients with infectious respiratory diseases. Meanwhile, the homecare segment is projected to register the fastest compound annual growth rate (CAGR) over the forecast period. This acceleration is due to the cost-effectiveness of home-based respiratory devices compared to prolonged hospital stays, alongside rising healthcare expenses globally.
Patients with chronic respiratory illnesses such as COPD or obstructive sleep apnea are increasingly opting for homecare solutions, supported by portable oxygen concentrators, CPAP/BiPAP devices, and remote patient monitoring systems. The growth of homecare is also bolstered by improvements in device portability, user-friendly designs, and reimbursement policies, making it a preferred choice for long-term respiratory management.
The Global Respiratory Care Devices Market Report is segmented on the basis of the following:
By Product
- Therapeutic Devices
- Ventilators
- Continuous Positive Airway Pressure (CPAP) Devices
- Bi-level Positive Airway Pressure (BiPAP) Devices
- Nebulizers
- Oxygen Concentrators
- Humidifiers
- Inhalers
- Metered-Dose
- Dry Powder
- Soft Mist
- High-Flow Nasal Cannula (HFNC) Systems
- Monitoring Devices
- Pulse Oximeters
- Fingertip
- Handheld
- Wearable
- Capnography Devices
- Spirometers
- Sleep Test Devices
- Polysomnography
- Home Sleep Apnea Test Systems
- Consumables and Accessories
- Breathing Circuits
- Masks & Nasal Cannulas
- Filters & Valves
- Tubing Systems
- Resuscitators & Ambu Bags
- Humidification Chambers
- Others
By Application
- Hospitals
- Intensive Care Units (ICUs)
- Emergency Departments
- General Wards
- Homecare
- Home Oxygen Therapy
- Sleep Apnea Management
- Chronic Obstructive Pulmonary Disease (COPD) Management
- Surgical Centers
- Preoperative & Postoperative Respiratory Support
- Anesthesia-Related Ventilation Support
- Clinics
- Pulmonology Clinics
- Sleep Disorder Clinics
- Asthma & Allergy Clinics
- Others
Impact of Artificial Intelligence in the Global Respiratory Care Devices Market
- Enhanced Disease Detection and Diagnosis: AI-powered respiratory devices can analyze patient data, imaging scans, and sensor readings to detect early signs of respiratory conditions such as asthma, COPD, and pneumonia. This improves diagnostic accuracy, reduces human error, and supports timely intervention.
- Personalized Treatment Plans: Machine learning algorithms can assess patient-specific data, including lung function tests, oxygen saturation levels, and medical history, to customize ventilation settings and oxygen therapy. This leads to improved patient outcomes and optimized care delivery.
- Predictive Analytics for Proactive Care: AI enables predictive modeling that forecasts potential respiratory complications, allowing healthcare providers to intervene before emergencies occur. This is particularly useful in chronic disease management and reducing hospital readmissions.
- Remote Monitoring and Telehealth Integration: AI-powered respiratory devices facilitate real-time data transmission and analysis, enabling healthcare professionals to remotely monitor patients and adjust treatments. This is especially valuable for homecare and rural healthcare accessibility.
- Workflow Optimization and Cost Reduction: AI automates routine processes such as patient data entry, device calibration, and monitoring alerts, allowing clinicians to focus on critical care. This boosts operational efficiency, reduces workload, and lowers healthcare costs.4
Global Respiratory Care Devices Market: Regional Analysis
Region with the Largest Revenue Share
North America is expected to dominate the market with 34.1% of revenue share in 2024 which is attributed to the rise in the number of individuals suffering from asthma, pulmonary disease, & other respiratory diseases. The region benefits from strong investments in R&D by major players such as Philips Respironics, ResMed, and Medtronic, which continually introduce technologically advanced devices, including AI-enabled ventilators and smart CPAP machines.
The growing prevalence of chronic respiratory diseases, such as COPD, asthma, and sleep apnea, is a major driver; according to the CDC, over 25 million Americans suffer from asthma alone. Additionally, the rising geriatric population, coupled with increased pollution-related respiratory conditions, has fueled demand for advanced respiratory support solutions.
Favorable government initiatives, such as funding for respiratory disease management programs and rapid emergency response capabilities during health crises (e.g., COVID-19), have further supported market growth. Telehealth integration and home care device adoption are also high in the region due to strong insurance coverage and a preference for decentralized care.
Moreover, North America hosts several leading medical device manufacturers and research organizations, enabling faster product approvals through streamlined FDA processes. The region's capacity to implement AI and IoT in respiratory devices enhances patient monitoring and compliance, reinforcing its market leadership.
Region with the Highest CAGR
Asia Pacific is projected to register the highest CAGR in the global respiratory care devices market, driven by rapid economic growth, expanding healthcare infrastructure, and rising awareness about respiratory health. Countries such as China, India, Japan, and South Korea are witnessing significant improvements in hospital facilities, increased government investments in healthcare, and the adoption of advanced respiratory technologies. The high prevalence of air pollution in major cities and the increasing incidence of respiratory disorders, such as COPD, tuberculosis, and asthma, are boosting demand for respiratory devices.
The region’s large and aging population also drives market growth, as elderly individuals are more prone to chronic respiratory diseases. Governments in APAC are implementing initiatives to expand access to affordable healthcare, including homecare respiratory solutions. Medical device manufacturers are increasingly targeting emerging markets with cost-effective, portable, and AI-enabled respiratory devices to meet the growing demand.
Furthermore, the COVID-19 pandemic accelerated the adoption of ventilators, oxygen therapy devices, and monitoring systems, prompting healthcare facilities to upgrade their respiratory care infrastructure. Technological advancements, such as smartphone-compatible spirometers and AI-driven diagnostics, are increasingly being integrated into respiratory care in APAC. Lower manufacturing costs and favorable government policies for foreign direct investment are attracting global players to set up production and R&D centers in the region. These factors, coupled with increasing health insurance coverage and rising disposable incomes, make Asia Pacific the fastest-growing region in the respiratory care devices market.
By Region
North America
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
The global respiratory care devices market is highly competitive, with leading players focusing on technological innovation, strategic partnerships, and product portfolio expansion to strengthen their market position. Major companies include Philips Healthcare, ResMed, Medtronic plc, Fisher & Paykel Healthcare, Drägerwerk AG, Masimo Corporation, and Hamilton Medical. These companies emphasize R&D investments to introduce advanced devices such as AI-powered ventilators, wireless CPAP systems, and portable oxygen concentrators.
Mergers, acquisitions, and collaborations are common strategies, enabling companies to expand geographically and enhance product capabilities. For instance, acquisitions of smaller niche companies allow larger firms to integrate specialized technologies into their product lines. Product innovation is particularly strong in the homecare respiratory devices segment, as demand for remote monitoring and telehealth compatibility rises.
The competitive landscape also features regional players in Asia Pacific and Europe, offering cost-effective solutions to target emerging markets. Regulatory approvals from agencies like the FDA, CE Mark, and CFDA are critical for competitive advantage, ensuring rapid market entry. Manufacturers are also prioritizing patient comfort, energy efficiency, and digital integration in device designs.
Sustainability and eco-friendly production practices are emerging as competitive differentiators, with companies aiming to reduce their carbon footprint while meeting global healthcare demands. The ongoing shift toward AI and IoT integration in respiratory care devices is redefining competition, as data-driven insights and predictive analytics become key features for clinical decision-making and patient management.
Some of the prominent players in the global respiratory care devices market are:
- Philips Respironics (Koninklijke Philips N.V.)
- ResMed Inc.
- Medtronic plc
- Fisher & Paykel Healthcare Limited
- Masimo Corporation
- Vyaire Medical, Inc.
- Drägerwerk AG & Co. KGaA
- GE HealthCare Technologies Inc.
- Chart Industries, Inc.
- Teijin Limited
- Invacare Corporation
- Hamilton Medical AG
- BMC Medical Co., Ltd.
- DeVilbiss Healthcare LLC
- Apex Medical Corp.
- Acare Technology Co., Ltd.
- OMRON Healthcare, Inc.
- 3B Medical, Inc.
- Heinen + Löwenstein GmbH & Co. KG
- Drive DeVilbiss International Inc.
- Others
Recent Developments
- July 2025: Philips Respironics launched an advanced portable ventilator featuring AI-based respiratory pattern detection, enhancing patient safety and comfort for both clinical and home use, aimed at improving remote monitoring capabilities and reducing hospital readmissions through predictive maintenance alerts.
- May 2025: ResMed Inc. announced a strategic acquisition of a European respiratory diagnostics company to expand its portfolio in sleep apnea and COPD monitoring, integrating AI-driven analytics for more accurate diagnosis and personalized therapy optimization across multiple care settings.
- March 2025: Fisher & Paykel Healthcare unveiled a next-generation heated humidification system at a global medical expo, offering improved secretion clearance and enhanced patient compliance, particularly targeting ICU ventilated patients and those requiring long-term oxygen therapy with higher comfort levels.
- January 2025: Vyaire Medical partnered with a leading AI software provider to integrate advanced machine learning algorithms into its pulmonary function testing systems, enabling earlier disease detection and more efficient workflow management for healthcare professionals in respiratory diagnostics.
- November 2024: Medtronic plc showcased its newly developed home-based respiratory monitoring system during a global healthcare innovation conference, featuring cloud connectivity and AI-based early warning alerts for high-risk patients with chronic respiratory conditions such as asthma and COPD.
- September 2024: Masimo Corporation introduced a multi-parameter wearable respiratory sensor at an international respiratory care symposium, designed to track oxygen saturation, respiratory rate, and lung function in real time, enabling proactive interventions and reducing hospital admissions for vulnerable patients.
- July 2024: Drägerwerk AG & Co. KGaA launched a new ICU ventilator platform with adaptive ventilation modes, AI-driven patient-ventilator synchrony optimization, and enhanced infection control features, catering to high-acuity respiratory care demands in hospitals worldwide.
- May 2024: Hamilton Medical announced an investment in expanding its production facilities to meet rising global demand for advanced ventilators, focusing on integrating AI-based predictive maintenance and automated weaning protocols for improved patient outcomes.
- March 2024: Hillrom (Baxter International Inc.) introduced a connected respiratory therapy system for home healthcare providers, enabling real-time patient data sharing with clinicians to optimize therapy adjustments and improve compliance monitoring in chronic respiratory disease management.
- January 2024: Invacare Corporation presented an upgraded portable oxygen concentrator at a major healthcare technology expo, featuring improved battery life, enhanced filtration, and AI-enabled oxygen delivery adjustments based on patient activity levels for greater mobility and independence.
Report Details
| Report Characteristics |
| Market Size (2025) |
USD 27.8 Bn |
| Forecast Value (2034) |
USD 60.5 Bn |
| CAGR (2025–2034) |
9.0 % |
| The US Market Size (2025) |
USD 8.0 Bn |
| Historical Data |
2019 – 2024 |
| Forecast Data |
2026 – 2034 |
| Base Year |
2024 |
| Estimate Year |
2025 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors, etc. |
| Segments Covered |
By Product (Respiratory Consumables, Nebulizers, Oxygen Concentrators), By Application (Hospitals, Surgical Centers, Clinics, Long Term Care Centers, Others) |
| Regional Coverage |
North America – US, Canada; Europe – Germany, UK, France, Russia, Spain, Italy, Benelux, Nordic, Rest of Europe; Asia-Pacific – China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, Rest of MEA |
| Prominent Players |
Philips Respironics (Koninklijke Philips N.V.), ResMed Inc., Medtronic plc, Fisher & Paykel Healthcare Limited, Masimo Corporation, Vyaire Medical, Inc., Drägerwerk AG & Co. KGaA, GE HealthCare Technologies Inc., Chart Industries, Inc., Teijin Limited, Invacare Corporation, Hamilton Medical AG, BMC Medical Co., Ltd., DeVilbiss Healthcare LLC, Apex Medical Corp., Acare Technology Co., Ltd., OMRON Healthcare, Inc., 3B Medical, Inc., Heinen + Löwenstein GmbH & Co. KG, Drive DeVilbiss International Inc., and Other Key Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days, and 5 analysts working days respectively. |
Frequently Asked Questions
The Global Respiratory Care Devices Market size is estimated to have a value of USD 27.8 billion in 2025 and is expected to reach USD 60.5 billion by the end of 2034.
North America has the largest market share for the Global Respiratory Care Devices Market with a share of about 34.1 % in 2025.
The US Respiratory Care Devices Market is projected to be valued at USD 8.0 billion in 2025. It is expected to witness subsequent growth in the upcoming period as it holds USD 16.5 billion in 2034 at a CAGR of 8.5%.
Some of the major key players in the Global Respiratory Care Devices Market are Massimo Corporation, Teleflex Incorporated, ResMed Inc. and many others.
The market is growing at a CAGR of 9.0 percent over the forecasted period.